Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY
Rheumatoid Arthritis

Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 1)

Share this Video
Copy Link
Published Online: Dec 21st 2020

We were delighted to speak to Anthony Sebba (Arthritis Associates, FL, USA) to discuss whether pain and inflammation are independent of each other in patients with rheumatoid arthritis. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials.’ (ABSTRACT NUMBER: 1237) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.

Questions

  1. What have we learned about the pathophysiological processes underlying pain in patients with rheumatoid arthritis (RA)? (0:35)
  2. What was the rationale for your study analysing pain and other patient-reported outcomes? (4:51)

Disclosures: Consultant or speaker for Genentech, Sanofi, Lilly, Gilead and Amgen.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).

Related Videos In Rheumatoid Arthritis
Rheumatic Diseases, Rheumatoid Arthritis
Developed by Touch
NRAS’s mission and impact on the RA community: Ailsa Bosworth, National Rheumatoid Arthritis Society

We had the pleasure of talking with Ailsa Bosworth, a patient advocate for rheumatoid arthritis (RA), and Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. In this interview, Ailsa explores NRAS’s profound impact on the RA community, and her role and experiences within the NRAS, and pivotal contributions to pioneering […]

Rheumatic Diseases, Rheumatoid Arthritis
Developed by Touch
A patient’s perspective – journey to diagnosis of seronegative rheumatoid arthritis: Ailsa Bosworth, National Rheumatoid Arthritis Society
Watch Time: 9 mins

We are joined by Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. Ailsa Bosworth is a patient advocate for rheumatoid arthritis (RA) and joins us in this interview to discuss her personal journal to, and following, diagnosis of seronegative RA and the challenges she has faced along the […]

Rheumatoid Arthritis
Developed by Touch
Peter Taylor, EULAR 2023: Current perspectives on the selectivity and safety of JAK inhibitors to target the pathophysiology of rheumatoid arthritis
Watch Time: 9 mins

Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]

Trending In Rheumatoid Arthritis:

NRAS’s mission and impact on the RA community: Ailsa Bosworth, National Rheumatoid Arthritis Society
Rheumatic Diseases, Rheumatoid Arthritis
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72